Circadian Ocular Perfusion Pressure and Ocular Blood Flow

Overview

The purpose of this study was to compare the short term effects of two intraocular pressure (IOP) lowering medications on ocular perfusion pressure (OPP), ocular blood flow, intraocular pressure, and blood pressure in patients with glaucoma. Ocular perfusion pressure (OPP) is defined as the difference between arterial blood pressure (diastolic and systolic) and intraocular pressure. The primary efficacy assessment is based on diastolic ocular perfusion pressure.

Full Title of Study: “Effects of Topical Hypotensive Drugs on Circadian Ocular Perfusion Pressure and Ocular Blood Flow in Patients With Open-Angle Glaucoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: January 2012

Interventions

  • Drug: Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension
    • Fixed combination ophthalmic suspension
  • Drug: Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution
    • Fixed combination ophthalmic solution

Arms, Groups and Cohorts

  • Other: AZARGA/COMBIGAN
    • AZARGA, followed by COMBIGAN, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
  • Other: COMBIGAN/AZARGA
    • COMBIGAN, followed by AZARGA, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.

Clinical Trial Outcome Measures

Primary Measures

  • Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6
    • Time Frame: Week 0, Week 6 (period-based)
    • Diastolic ocular perfusion pressure (DOPP) is defined as the difference between diastolic arterial pressure and intraocular pressure. Diastolic arterial pressure was measured with a calibrated automated sphygmomanometer. Intraocular pressure was measured with a calibrated pneumatonometer. A lower DOPP indicates a lower optic blood supply, which can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).

Secondary Measures

  • Mean Change From Baseline in Circadian Diastolic Ocular Perfusion Pressure at Week 6
    • Time Frame: Week 0, Week 6 (period-based)
    • Circadian diastolic ocular perfusion pressure (COPP) is defined as the variations in diastolic OPP during the day and night. Diastolic ocular perfusion pressure was calculated at 7 timepoints over a 24-hour period. Changes in the diastolic ocular perfusion pressure rhythm throughout the day (outside the normal range) may affect glaucoma progression.
  • Mean Change From Baseline in Mean Flow Value in the Superotemporal Peripapillary Retina at Week 6
    • Time Frame: Week 0, Week 6 (period-based)
    • Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.
  • Mean Change From Baseline in Mean Flow Value in the Inverotemporal Peripapillary Retina at Week 6
    • Time Frame: Week 0, Week 6 (period-based)
    • Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.
  • Mean Change From Baseline in Intraocular Pressure (IOP) at Week 6
    • Time Frame: Week 0, Week 6 (period-based)
    • Intraocular pressure (IOP) is defined as the fluid pressure inside the eye. Intraocular pressure was measured with a calibrated pneumatonometer at 7 time points over a 24-hour period. High IOP (outside the normal range) can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).
  • Mean Change From Baseline in Diastolic Blood Pressure at Week 6
    • Time Frame: Week 0, Week 6 (period-based)
    • Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Diastolic blood pressure refers to the minimum pressure, that is, the pressure between heartbeats. Diastolic glood pressure was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.
  • Mean Change From Baseline in Systolic Blood Pressure at Week 6
    • Time Frame: Week 0, Week 6 (period-based)
    • Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Systolic blood pressure refers to the maximum pressure, that is, the pressure while the heart is beating, and was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.
  • Mean Change From Baseline in Vascular Resistance in the Central Retinal Artery at Week 6
    • Time Frame: Week 0, Week 6 (period-based)
    • Vascular resistance in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.
  • Mean Change From Baseline in Vascular Resistance in the Ophthalmic Artery at 6 Weeks
    • Time Frame: Week 0, Week 6 (period-based)
    • Vascular resistance in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.
  • Mean Change From Baseline in End Diastolic Velocity in the Ophthalmic Artery at Week 6
    • Time Frame: Week 0, Week 6 (period-based)
    • End diastolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.
  • Mean Change From Baseline in Peak Systolic Velocity in the Ophthalmic Artery at Week 6
    • Time Frame: Week 0, Week 6 (period-based)
    • Peak systolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.
  • Mean Change From Baseline in Peak Systolic Velocity in the Central Retinal Artery at Week 6
    • Time Frame: Week 0, Week 6 (period-based)
    • Peak systolic velocity in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.

Participating in This Clinical Trial

Inclusion Criteria

  • Sign Informed Consent.
  • Diagnosis of open-angle glaucoma in at least one eye.
  • Requires more than one IOP-lowering medication.
  • IOP measurements at Screening, Safety, and Eligibility/Period 1 Baseline Visits as specified in protocol.
  • Able to discontinue all IOP-lowering medication prior to Eligibility Visit and for 4 weeks between treatment periods.
  • Willing to complete all required study visits.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • Female of child-bearing potential if pregnant, lactating, or not using highly effective birth control measures.
  • Severe central visual field loss in either eye.
  • Previous glaucoma surgery in the study eye.
  • Intraocular surgery in the study eye within 3 months prior to the Screening Visit.
  • Wears contact lenses.
  • Allergy/hypersensitivity to study medication.
  • Cannot safely discontinue use of glucocorticoid medication.
  • Uses medication that could affect IOP or blood pressure.
  • Recent use of high-dose aspirin.
  • Bronchial asthma or severe chronic obstructive pulmonary disease.
  • Diabetic retinopathy.
  • Any abnormality preventing reliable tonometry.
  • Any severe illness or condition unsuitable for the study, in the opinion of the investigator.
  • Other protocol-defined exclusion criteria may apply.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Alcon Research
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.